Prescription-drug middlemen face mounting bipartisan criticism on Capitol Hill

Date:

July 23, 2024

Top executives at the largest U.S. pharmacy-benefit managers sought to defend their business practices on Capitol Hill on Tuesday, as lawmakers on both sides of the aisle excoriated the industry’s impact on the cost and accessibility of prescription drugs.

Source link

Cindy Crawford Recreates Her ’90s Supermodel Uniform For a Night Out

Vehicle Remarketing New Job Roles Roundup

Alexandra Williams

Alexandra Williams is a writer and editor. Angeles. She writes about politics, art, and culture for LinkDaddy News.

Prescription-drug middlemen face mounting bipartisan criticism on Capitol Hill

Recent posts

The owner of Bed Bath & Beyond and Overstock says it’s winning back customers, and shares are rallying

Gold prices look to settle at 1-month high as silver jumps nearly 4%

AI chip startup Cerebras files for IPO, in market dominated by Nvidia

Macy’s stock tumbles after takeover talks with Arkhouse and Brigade were ended

Freight demand is weak, but cost cuts help C.H. Robinson boost profits. Shares are rallying.

Under Armour’s ‘affinity for the underdog’ helps send stock toward record gain

After its August selloff, the U.S. dollar may face more downside risk ahead

Southwest Airlines Chairman Kelly to retire after urging from activist Elliott

Oil prices remain lower amid Gaza ceasefire hopes as investors prepare for PCE data

Norfolk Southern CEO change brings stability but governance questions linger, says analyst

This chart shows gold vs. the stock market since Bernanke’s famous helicopter drop speech

Larry Summers says the Fed and investors are ‘badly wrong’ on inflation’s path

Can Disney, NBC and Amazon make money from their NBA deal? That’s complicated, analysts say.

Harris sees ‘next generation of breakthroughs’ built by U.S. workers. AI, crypto could benefit.

Marriage proposals are still falling but should bottom this year, Signet says

Related articles

Investors are bracing for higher-for-even-longer interest rates

RFK Jr. is not a fan of weight-loss drugs or vaccines. Stocks are tanking.

Manufacturing activity surges in New York region to highest level in nearly three years

RFK Jr. would rattle health markets as head of HHS, but his confirmation is far from certain, analyst says

Vaccine-maker stocks like Moderna, Pfizer drop as Trump picks RFK Jr. to lead HHS

Powell says Fed doesn’t need to hurry to cut interest rates

Biogen’s stock rises after E.U. regulator reverses negative view of Alzheimer’s drug

Off-price retailers could thrive, BofA says, citing this bullish data point

Company

Follow us